DNA sequencing

DiaCarta's Multivariant COVID-19 Test Accurately Detects the Omicron Variant

Tuesday, November 30, 2021 - 3:47pm

Last week, the World Health Organization (WHO) classifieda new SARS-CoV-2 variant, the B.1.1.529,as a Variant of Concern andclassified it theOmicron variant.

Key Points: 
  • Last week, the World Health Organization (WHO) classifieda new SARS-CoV-2 variant, the B.1.1.529,as a Variant of Concern andclassified it theOmicron variant.
  • Since the identification of the Omicron variant in Botswana last week, it was subsequently detected in South Africa with confirmed cases nearing 100 and rising.
  • As the Omicron variant mutations are similar to those in the Delta variant, the expectation is that it will transmit rapidly across the world.
  • Using this technology, the company has developed its highly sensitive, early detection ColoScape Colorectal Cancer test using blood.

PathoQuest Receives GMP Certification for Its NGS-based Quality Control Testing Services of Biological Drugs

Wednesday, November 24, 2021 - 12:00pm

PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.

Key Points: 
  • PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.
  • View the full release here: https://www.businesswire.com/news/home/20211124005881/en/
    This GMP certification acknowledges PathoQuest's testing activities meet the established high-quality control standards required by the biopharmaceutical industry.
  • The GMP certification for our biosafety testing services completes our GLP certificate obtained in January 2020 and the Pharmaceutical Establishment status achieved in September 2020.
  • Gaining this GMP certification is a major milestone in the implementation of PathoQuests growth strategy and strengthens our leadership in the quality control testing of biologics, commented Jean-Francois Brepson, PathoQuests CEO.

ACT Genomics and Sanomics Merge to Unleash Hong Kong's Global Potential in Healthcare Technology

Monday, November 22, 2021 - 7:57am

Both ACT Genomics and Sanomics are park companies of Hong Kong Science and Technology Parks Corporation (HKSTP) and located in the Hong Kong Science Park.

Key Points: 
  • Both ACT Genomics and Sanomics are park companies of Hong Kong Science and Technology Parks Corporation (HKSTP) and located in the Hong Kong Science Park.
  • The merger is set to create an integrated oncology diagnostic powerhouse in Asia and unleash the global potential of healthcare technology (healthtech) in Hong Kong, the Greater Bay Area and beyond.
  • Sunny Chai, Chairman of Hong Kong Science & Technology Parks Corporation, Mr. Alfred Sit, Secretary for Innovation and Technology, and Ms. Annie Choi, Permanent Secretary for Innovation and Technology.
  • About ACT Genomics Holdings Co. Ltd.
    ACT Genomics is an innovation-driven cancer solution provider with offices in Hong Kong, Taipei, Singapore, Tokyo, Bangkok and Wales (UK).

Mindera Health™ announces publication of positive results from STAMP-1 and STAMP-2 studies

Tuesday, November 16, 2021 - 4:30pm

These positive results from the STAMP studies address this need to improve patient outcomes while significantly lowering healthcare system costs by reducing payer wasted spend and increasing net savings.

Key Points: 
  • These positive results from the STAMP studies address this need to improve patient outcomes while significantly lowering healthcare system costs by reducing payer wasted spend and increasing net savings.
  • The Mindera Health platform uses a dermal biomarker patch that takes only minutes to extract vast transcriptomic information.
  • Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin.
  • Mindera Health is a CLIA and CAP certified Laboratory and has received ISO 13485:2016 certification.

Mursla Announces Key Appointments to Advisory Board

Wednesday, November 17, 2021 - 8:00am

Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.

Key Points: 
  • Mursla, a liquid biopsy company, is pleased to announce the appointment of Professor Bernd Giebel, Dr Daniel Delubac and Professor Emmanuel Rautou to its Advisory Board.
  • He used to sit on the scientific advisory board of EVOX Therapeutics.
  • Mursla is a Cambridge-based liquid biopsy company based on a novel tech platform, ExoPheno, which traces diseases in biofluids via exosomes.
  • Using nanoelectronics and bioengineering, Mursla is developing its platform to detect dozens of cancer types with a single blood test, starting with liver cancer surveillance.

DNA Sequencing Markets, 2030 - ResearchAndMarkets.com

Friday, November 12, 2021 - 4:47pm

The "DNA Sequencing - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "DNA Sequencing - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
  • This report briefly reviews the basics of human genome variations, development of sequencing technologies, and their applications.
  • The value of the DNA sequencer market in 2020 is described with estimates for 2024 and 2030.
  • Various applications of sequencing are described including those for genetics, medical diagnostics, drug discovery, and cancer.

Fulgent Genetics Launches At-Home Neutralizing Antibody Test for COVID-19

Wednesday, October 27, 2021 - 1:00pm

Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has launched an antibody test for COVID-19 which will specifically target neutralizing antibodies.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent or the Company), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced that it has launched an antibody test for COVID-19 which will specifically target neutralizing antibodies.
  • Fulgent aims to empower individuals with better data on their potential resistance levels to COVID-19 by making antibody testing readily available to consumers through its Picture Genetics platform.
  • Unlike typical antibody tests that detect all antibodies in patients, Fulgents antibody test will specifically detect the level of neutralizing antibodies in patients from a recent COVID-19 infection, or those who have been vaccinated against the virus.
  • The addition of COVID-19 neutralizing antibody testing complements the Companys existing RT-PCR and Next Generation Sequencing based tests for the virus.

Insights on the Cancer/Tumor Profiling Global Market to 2027 - Featuring Caris Life Sciences, Illumina and Qiagen Among Others - ResearchAndMarkets.com

Tuesday, October 26, 2021 - 6:09pm

The "Cancer/Tumor Profiling - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cancer/Tumor Profiling - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Immunoassays, one of the segments analyzed in the report, is projected to record a 9.1% CAGR and reach US$3.6 Billion by the end of the analysis period.
  • In the global Next Generation Sequencing segment, USA, Canada, Japan, China and Europe will drive the 10.2% CAGR estimated for this segment.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

Mindera Health™ announces first patient enrolled in the MATCH Study: a clinical utility evaluation of the impact of Mind.Px™ on response rates of psoriasis patients who are prescribed biologics

Thursday, October 21, 2021 - 5:00pm

MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.

Key Points: 
  • MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis.
  • According to a recent publication reporting data from the largest independent psoriasis registry (CorEvitas),1 real-world patient response rates to hyper-expensive biologics were observed to be approximately 52%.
  • These low response rates often lead to switching of therapies and massive wasted healthcare spending.
  • Subsequent Next-Generation Sequencing of the extracted RNA allows Mindera Health scientists to take a genetic and transcriptomic snapshot of the skin.

New Ultra-Sensitive Leukemia Blood Test Delivered by Sysmex Inostics

Wednesday, October 20, 2021 - 3:30pm

BALTIMORE, Oct. 20, 2021 /PRNewswire/ -- Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML). A global leader and pioneer in blood-based, ultra-sensitive molecular testing for oncology, the company's new test uses a targeted Next Generation Sequencing (NGS) panel.

Key Points: 
  • BALTIMORE, Oct. 20, 2021 /PRNewswire/ -- Sysmex Inostics has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML).
  • This new test, AML-MRD-SEQ, adds to the portfolio of ultra-sensitive Plasma-Safe-SeqS technology NGS tests available through Sysmex Inostics' CLIA lab services in Baltimore, Maryland.
  • Sysmex Inostics, Inc., a US-based Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators cost-effective and ultra-sensitive quantitative liquid biopsy solutions.
  • Sysmex Inostics offers a portfolio of highly sensitive NGS panels through its CLIA-certified laboratory in Baltimore, Maryland.